Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
Express Scripts
Moodys
Baxter

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

Litigation Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)


Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in In Re: Actos Direct Purchaser Antitrust Litigation

Details for In Re: Actos Direct Purchaser Antitrust Litigation (S.D.N.Y. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-04-27 1 Patent No. Issue Date Patent Expiry 6,150,383 (the…its patent information that the two patents—United States Patent Nos. 5,965,584 (the “’584 Patent”) and…manufacturer’s patents and patent information for accuracy or trustworthiness. In listing patents and patent information…the ’777 Patent, the ’584 Patent, and the ’404 Patent, Takeda submitted eight other patents to the FDA…the ’584 Patent and the ’404 Patent as drug product patents claiming ACTOS only if the patents in fact External link to document
2019-10-08 131 Memorandum & Opinion two other patents-U.S. Patent Nos. 5,965,584 (the "'584 patent") and 6,329,404 (the "… several patents related to its diabetes medicines. The first of those patents, U.S. Patent. No. 4,687,777…hereinafter, "the Patents") as both drug product patents and method-of-use patents-and improperly … Normally, inventors obtain patents for their brand-name drugs. Patents that protect a drug may include…such patents must be submitted with an NDA is at the heart of this case. For each patent that External link to document
2016-01-06 54 Patent No. Issue Date Patent Expiry 6,150,383 (the…listed three additional patents – the ’042 Patent, the ’043 Patent, and the ’090 Patent – as applicable method-of-use…Takeda asserted in its patent information that the two patents – United States Patent Nos. 5,965,584 (the…misleading patent information regarding the ’584 Met Combo Patent and ’404 Insulin Combo Patent for ACTOS… drug substance patent – U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) – expired on January External link to document
2016-01-07 55 Patent No. Issue Date Patent Expiry 6,150,383 (the…listed three additional patents – the ’042 Patent, the ’043 Patent, and the ’090 Patent – as applicable method-of-use…Takeda asserted in its patent information that the two patents – United States Patent Nos. 5,965,584 (the…misleading patent information regarding the ’584 Met Combo Patent and ’404 Insulin Combo Patent for ACTOS… drug substance patent – U.S. Patent No. 4,687,777 (the “’777 ACTOS Compound Patent”) – expired on January External link to document
2016-01-27 62 medications: U.S. Patent Nos. 5,965,584 (“’584 patent”) and 6,329,404 (“’404 patent”), both of which …U.S. Patent No. 4,687,777 (“’777 patent”), which expired in January 2011. Id. ¶ 158. Two patents claim…traditional patent settlement, Teva (the alleged patent infringer) agreed to pay Takeda (the patent holder… the underlying patent infringement cases, or (2) the supposed weakness of the patent claims would have…relating to the ACTOS and ACTOplus met patent litigations and patent settlements are no different from those External link to document
2016-01-27 65 584 patent at 18:19-21, 18:65-67 (claims 4 and 10). Takeda received U.S. Patent No. 6,329,404, which…pioglitazone patents, including the ’777, ’584, and ’404 patents, as well as the method-of-use patents, for … and ’404 patents only as “method- of-use” patents for ACTOS and never as “product” patents, as shown…Takeda had not described the patents as “product” patents in its patent submission letters to the FDA…to list a patent. For each patent, pioneer drug companies are required to submit the patent if and only External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
McKinsey
McKesson
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.